Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Sima Diab/Bloomberg via Getty Images

Gilead Sciences collected $2.8 billion of revenue in 2020 from its IV coronavirus treatment Veklury, also known as remdesivir.

The big picture: The pandemic has created a massive business that Gilead simply did not have before.

  • The company expects Veklury, a drug shown to have only modest benefits for patients, to generate up to $3 billion this year as the virus continues to spread.

Flashback: Gilead's gross profit margin on remdesivir sales to the government is about 90%.

Go deeper

Updated 4 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios

Updated Feb 4, 2021 - Health

Wisconsin governor issues new mask mandate after state GOP kills previous order

Wisconsin Gov. Tony Evers. Photo: Morry Gash-Pool via Getty Images

Wisconsin Gov. Tony Evers (D) on Thursday issued a new statewide mask mandate almost immediately after the state Legislature voted to repeal his previous order.

Why it matters: Evers' attempts to combat COVID-19 have faced pushback from Republicans since early in the pandemic. Even with a new order, the Legislature could again vote to repeal the mask requirement.

Feb 4, 2021 - Health

LGBTQ Americans at heightened risk for severe coronavirus symptoms, CDC says

Illustration: Aïda Amer/Axios

The Centers for Disease Control and Prevention found that the coronavirus pandemic disproportionately affects LGBTQ Americans compared to their straight peers, per an analysis released Thursday.

Why it matters: The report is one of the agency's first public examinations of how the coronavirus is affecting LGBTQ people, and comes amid an information drought as advocates take the reins on gathering data.